Editas Medicine Inc (EDIT)

NASDAQ
18.30
+0.31(+1.72%)
  • Volume:
    696,357
  • Day's Range:
    18.10 - 18.91
  • 52 wk Range:
    9.59 - 73.03

EDIT Overview

Prev. Close
17.99
Day's Range
18.1-18.91
Revenue
31.8M
Open
18.89
52 wk Range
9.59-73.03
EPS
-2.7
Volume
696,357
Market Cap
1.26B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,738,514
P/E Ratio
-7.19
Beta
2.02
1-Year Change
-69.01%
Shares Outstanding
68,719,250
Next Earnings Date
09 Nov 2022
What is your sentiment on Editas Medicine?
or
Vote to see community's results!

Editas Medicine Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Editas Medicine Inc Analysis

Editas Medicine Inc Company Profile

Editas Medicine Inc Company Profile

Employees
264

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuyBuySell
Technical IndicatorsStrong BuySellBuyStrong BuyStrong Sell
SummaryStrong BuyNeutralBuyStrong BuyStrong Sell
  • I'm long!
    0
    • Still long?
      0